Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

INTRODUCTION: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gounant, Valérie, Ferré, Valentine Marie, Soussi, Ghassen, Charpentier, Charlotte, Flament, Héloïse, Fidouh, Nadhira, Collin, Gilles, Namour, Céline, Assoun, Sandra, Bizot, Alexandra, Brouk, Zohra, Vicaut, Eric, Teixeira, Luis, Descamps, Diane, Zalcman, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593625/
https://www.ncbi.nlm.nih.gov/pubmed/34798306
http://dx.doi.org/10.1016/j.jtho.2021.10.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593625/
https://www.ncbi.nlm.nih.gov/pubmed/34798306
http://dx.doi.org/10.1016/j.jtho.2021.10.015

Ejemplares similares